Key Dates

Related Announcements

PAR-22-174 - Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)

Issued by

National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to correct the Non-Responsive Applications criteria in Funding Opportunity Announcement (FOA) PAR-22-174, “Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)".

The following section of PAR-22-174 has been modified:

Section I. Funding Opportunity Description

Non-Responsive Applications

Currently Reads

Applications with the following attributes will be deemed non-responsive and will not be reviewed:

• Applications that are first-in-human studies.
• Applications that only propose to write a protocol or manual, develop infrastructure, or implement an already fully designed trial.
• Applications that include purely mechanistic work or contain animal studies.
• Applications that lack a milestone plan, an organization plan and/or a stakeholder engagement plan.

Modified to Read (changes shown in bold italics):

Applications with the following attributes will be deemed non-responsive and will not be reviewed:

• Applications that are first-in-human studies.
• Applications that only propose to write a protocol or manual, develop infrastructure, or implement an already fully designed trial.
• Applications that include purely mechanistic work or contain animal studies.
• Applications that lack a milestone plan, stakeholder engagement plan, and/ or future clinical trial description.

All other aspects of the FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Brandy Heckman-Stoddard, Ph.D., M.P.H.
National Cancer Institute (NCI)
Telephone: 240-276-7048
Email: [email protected]